Alnylam Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Alnylam Pharmaceuticals (ALNY).

Price Target Range — 7 Quarters

Analyst Consensus — 21 Analysts

1S.Buy

18Buy

2Hold

Consensus RatingBuy# Analysts21Avg. Consensus PT$418Upside to Avg. PT+84.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	UBS	Joon Lee	Assumes	Buy	$550→$354
Oct 14, 2026	Citigroup	Eric Joseph	PT Cut	Buy	$340→$320
Oct 14, 2026	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$256→$253
Oct 8, 2026	RBC Capital	Luca Issi	PT Cut	Outperform	$350→$345
Sep 30, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$375→$369
Sep 21, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$455
Sep 8, 2026	Jefferies	Faisal Khurshid	PT Raise	Hold	$230→$260
Sep 2, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$455
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform	$318
Aug 14, 2026	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$316→$256
Aug 4, 2026	Truist Securities	Danielle Brill	PT Cut	Buy	$410→$315
Aug 4, 2026	HC Wainwright & Co.	Patrick R. Trucchio	PT Cut	Buy	$485→$455
Aug 3, 2026	Raymond James	Martin Auster	Upgrade	Outperform→Strong Buy	$420
Aug 3, 2026	Citigroup	Eric Joseph	PT Cut	Buy	$380→$340
Aug 3, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$527→$450
Jul 31, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$400→$375
Jul 31, 2026	RBC Capital	Luca Issi	PT Cut	Outperform	$445→$350
Jul 31, 2026	Morgan Stanley	Michael Ulz	PT Cut	Equal-Weight	$400→$300
Jul 31, 2026	Oppenheimer	Kostas Biliouris	PT Cut	Outperform	$500→$350
Jul 31, 2026	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$377→$316

Analyst Ratings News

PRO
Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320

Citigroup analyst Eric Joseph maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $340 to $320.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $253

Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $256 to $253.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $345

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $350 to $345.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $375 to $369.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $455 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $455 price target.

Benzinga Newsdesk

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320

PRO
Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $253

PRO
RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $345

PRO
JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369

PRO
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

People Also Watch

People Also Watch

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320

PROWells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $253

PRORBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $345

PROJP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369

PROHC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

PROHC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

People Also Watch

People Also Watch

PRO
Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320

PRO
Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $253

PRO
RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $345

PRO
JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369

PRO
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target